ECNP Daily News Saturday

2 Frans de Waal delivers Keynote Lecture on prosocial primates The official newspaper of ECNP Congress 2015

Issue 1 Saturday 29 August 2015

3 Early-life stress ‘ticking time bomb’ for adult health 6 Highlights from the 28th ECNP Congress 8 A long road for clinical biomarkers?

13 Translational insights into compulsivity 16 Drug repurposing: The US experience

ECNP MATTERS DAILY NEWS neuroscience applied

Welcome to Amsterdam

I

t’s difficult to make an organisation that already does things well, do them even better. As a foundation directed to the understanding and translation of research for the benefit of patients, especially those patients with a psychiatric disorder, ECNP has had an exceptional year, which will culminate in an exceptional congress.

The EU’s Innovative Medicines Initiative has provided a great model for funding the translational research that is the core activity of ECNP. It is

therefore very exciting that the ECNP network for experimental medicine has recently won the opportunity to bid for a major grant under the IMI programme (PRISM). If successful, the ECNP office would participate directly in one of the work packages, which is a major first.ECNP has been a key participant in re-structuring the European Brain Council so that we get the message across in Brussels that research into mental illness is undervalued.

In Nice last March our consultation meeting looked at the exciting potential role of diagnostics in psychiatry; we are actively seeking ways to interest diagnostics and biotech companies in using ECNP as a vehicle for developing their applied neuroscience.

We are seeing the fruits of our new information strategy, which I hope will help to get balance into the public debate on treatment in psychiatry. It means being proactive in commenting on news stories, which takes time, but is clearly successful.

In a similar vein, the nomenclature project is progressing as planned. The challenge now is behavioural change, which occurs at very unpredictable speed and in very unpredictable measure.

These initiatives have and will continue to nourish our approach to the content of the congress.

ECNP aims to offer you the best in applied and translational neuroscience over these four days. There would be no congress, however, without the participants who literally create the atmosphere that inspires the science.

Guy Goodwin ECNP President

Highlights this year Symposia on Saturday We start the scientific sessions today, Saturday, to make a tighter four-day meeting that’s maximally timeefficient for participants. The first five sessions will be held at 16.50–18.30, just before the Keynote session.

Keynote session The Keynote session (today at 18.45–20.15) is our official welcome to all congress participants. The Keynote lecture will be given by renowned primatologist Frans de Waal on ‘Prosocial primates: co-operation and empathy’.

Plenary lectures Six plenary lectures will anchor the programme, two a day on Sunday-Tuesday, at 11.00 and 13.45. Our lecturers this year are Tallie Z. Baram, USA; Andreas Heinz, Germany; ECNP Neuropsychopharmacology Award winner Francesc Artigas, Spain; Brain Prize Award winner Trevor W. Robbins, United Kingdom; Anna Monika Prize Award winner Ned H. Kalin, USA; and Marion Leboyer, France.

Awards The ECNP Neuropsychopharmacology Award will be conferred this year on Francesc Artigas, Spain, and the ECNP Media Award on Mary G. Baker, MBE, United Kingdom. Also, for the first time, the Anna Monika Prize will be presented at the ECNP Congress, jointly to Ned H. Kalin, USA, and Carmine M. Pariante, United Kingdom.

Patient session For the first time this year, we will have a dedicated patient session for issues specifically concerned with patient care and welfare. It will be held this afternoon at 14.00–14.45.

Biomarkers session In the Clinical Research track this evening (16.50–18.30), the outputs of ECNP’s special meeting on biomarkers in the clinic, held earlier this year, will be presented and new directions marked out.

Regulatory update session This year also sees the second of our highly successful dialogue sessions with the European Medicines Agency (EMA). This will take place on Monday evening (accompanied by a light dinner).

Career development sessions As part of our commitment to junior scientists, we continue career development sessions, with a career veteran discussing practical, day-to-day career challenges, such as ‘how to give an effective talk’ and ‘how to make a winning poster’ in an open, interactive format.

2 ECNP Daily News Saturday

www.ecnp.eu

THE 28TH ECNP CONGRESS

KL.01: Keynote Session Auditorium Saturday 18:45–20:15

Prosocial primates

What we can learn about cooperation and empathy

T

his year’s Keynote Lecture will not in whether they cooperate, but be delivered by the eminent instead with their comprehension of primatologist Frans de Waal – a cooperation – whether they understand Charles Howard Candler Professor at that they need a partner, and what that Emory University in Atlanta, Georgia, partner needs to do.3 USA, and director of the Living Links With regards to translating this Center at the Yerkes National Primate information, Professor de Waal gave Research Center. His illustrious career some perspective: “I’m not sure how I has inspired the field of primate cogni- would use this in a medical or clinical tion, and his work continues to prosper setting, but I do believe that this rearound themes of empathy, cooperation search will create a different mind-set.” and fairness.

Indeed, he challenges the notion that Professor de Waal’s lecture – taking humans, being so sophisticated, have place this evening in the Auditorium recently created these unique social – will focus on the level of cooperation constructs as a cultural invention, or observed between primate societies, that these “rules” are determined by and how this cooperation is based on education. “My work shows that emempathy. ECNP Daily News had the pathy and cooperation are very ancient pleasure of talking with Professor de tendencies that we have inherited from Waal to further explore what he will be primates; and that they’re not just part sharing with the audience: “Empathy of human nature, but part of animal is a big topic in the neurosciences, and nature,” he said. not just in primates: empathy has been “This work shows that the ‘good’ shown in many studies of rats and side of humanity has an evolutionidea. Many animals live in societies, and mice, and I believe that it is found in all ary background, and questions the both cooperation and solidarity are very mammals,” he said. belief that humans are common characteristics.”

He delved deeper: inherently nasty and Professor de Waal also considered “We are biased towards “Many believe the origin selfish.” an interesting challenge: how can we individuals who are of empathy is maternal Professor de Waal maintain empathy when our ‘tribe’ is similar to us, so the care, because females – noted that in some expanding, living in large cities under flip side to empathy is from human to elephant ways, working with globalisation? “Empathy is extremely bithat we have trouble – need to take care of animals – where emoased in humans, in chimps, and we also empathising with their young. They need tions can be measured have seen it in rodent studies,” he said. strangers.” to pay attention to when – is easier than workDescribing a study of yawn contaFrans de Waal they are distressed, huning with humans, who gion in chimpanzees, which is related gry or in danger; they can hide or deny their to empathy, and stems from the primineed to be sensitive to feelings: “In a way I tive motor memory mimicry system,6 the emotions of their young, and that’s am happy to work with animals who Professor de Waal noted that chimps where the sensitivity to someone else is cannot fill out questionnaires because will yawn when they see chimps that learned from.”

I am not sure I trust what people tell they know also yawning, but are unafProfessor de Waal noted that this themselves or others.” fected by chimps they do not know. would explain the sex differences He continued: “Animals elicit emo“We live in large-scale societies observed in the expression of empathy, tions, which are external manifestations where there are lots of people who are which tends to be a more female charthat I can measure and study. We study not like us, and we have to deal with acteristic, and is demonstrated in adult fear in rats,4 and love in voles,5 but the strangers,” said Professor de Waal. “We humans reacting more empathetically feelings of an animal are basically inacwhen given oxytocin, which is considcessible to me, as are those of a human.”

“Empathy and cooperation are ered to be a maternal hormone.1 Professor de Waal then discussed very ancient tendencies that we “Cooperation is quite a different how research supporting intrinsic coophave inherited from primates… beast, as it can be done for entirely eration and empathy could help to influthey’re not just part of human selfish reasons, for example where two ence society as a whole: “There has been nature, but part of animal nature.” individuals will get something that they a shift in opinion, after the crises of 2008, 2 Frans de Waal could never get alone, ” said Professor when people lost confidence in econode Waal. “And that’s found widespread mists. At that time, the use of the words in the animal kingdom, not just in ‘empathy’ and ‘solidarity’ in newspaper mammals.” articles and internet blogs increased are biased towards individuals who are While Professor de Waal has robust dramatically. A society based purely on similar to us, so the flip side to empathy evidence demonstrating cooperation money and market forces is really not is that we have trouble empathising across many species, his interest lies tenable, and my work contributes to this with strangers. But we are meeting that

challenge by exposing ourselves to the perspectives of others with television and the internet – we see videos of people who are affected by various issues or disasters, and we start to empathise, even though they are very far away, and they may be very different to us.”

Professor de Waal will deliver his lecture ‘Prosocial primates: cooperation and empathy’ during this evening’s Keynote Session, taking place at 18:45–20:00 in the Auditorium. The lecture will be followed by a Welcome Reception in the Auditorium Lounge.

References 1. Ross HE, Young LJ. Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Frontiers in neuroendocrinology.

2009;30(4):534-47.

2. de Waal FB, Suchak M. Prosocial primates: selfish and unselfish motivations. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2010;365(1553):2711-22.

3. Plotnik JM, Lair R, Suphachoksahakun W, de Waal FB. Elephants know when they need a helping trunk in a cooperative task. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(12):5116-21.

4. Graham BM, Langton JM, Richardson R. Pharmacological enhancement of fear reduction: preclinical models. British journal of pharmacology.

2011;164(4):1230-47.

5. Carter CS. Neuroendocrine perspectives on social attachment and love. Psychoneuroendocrinology. 1998;23(8):779-818.

6. Campbell MW, de Waal FB. Chimpanzees empathize with group mates and humans, but not with baboons or unfamiliar chimpanzees. Proceedings Biological sciences / The Royal Society.

2014;281(1782):20140013.

ECNP Daily News Saturday 3

www.ecnp-congress.eu

PLENARY LECTURES

PL.01.01: Neural correlates of chronic early-life stress Auditorium Sunday 11:15–12:00

Early-life stress:

A ticking time bomb for adult emotional health?

T

he first lecture of this year’s ECNP Congress will take place tomorrow morning, with Tallie Z. Baram (University of California-Irvine, CA, USA) taking the audience through neural correlates of chronic early-life stress, with the core message being that early-life adversity is incredibly influential on emotional health and emotional disease later in life.

“Unlike the effect of stress during adulthood, the consequences can be permanent, by way of reprogramming in the brain,” she told ECNP Daily News. “The other unique aspect of early-life stress is that whatever causes stress later in life doesn’t seem to do so earlier in life.”

Professor Baram expanded on this concept, first noting that there are some very special factors that perturb the brain early in life, which then can cause emotional stress. From her own work, and that of others, it has been shown that the consistency and predictability of signals is an important – if not the most important – parameter. “If you have fragmented and unpredictable environmental experiential signals that make their way into the developmental brain, that creates terrible stress, and also seems to be involved in how early-life stress ‘reprograms’ the brain,” she said.

“But we don’t really know if it is the stress itself, or the signals that provoke the stress, that cause changes in brain function that then translates into later-life resilience or vulnerability.”

Other questions that persist include how ‘stress’ – however that is defined – actually causes vulnerability or resilience. To that end, Professor Baram has focused on rodent models that have examined the connectivity of neuronal populations, and how they contribute to

vulnerability and resilience.

“What part of the brain does early-life experience include stress change? Are all neurons changed? Is it a particular part of the brain?” she questioned.

“The answer is not fully known, but we do know that some parts of the brain are indeed changed very early on – a classical one being the hypothalamus, where stresssensitive neurons reside. And we have shown, as others have as well, that the number of excitatory synapses to stresssensitive neurons is governed by early-life experience. This may be stress – which increases the number of synapses – or the opposite of stress, i.e. optimal, wonderful, maternal care, which reduces excitatory synapses to stress-sensitive neurons in the hypothalamus.”

In addition to altering the communication between brain cells, this change in excitatory synapse number also changes what happens inside stress-sensitive neurons.

As excitatory synapses govern a variety of intracellular mechanisms – including those mediated by calcium – this in turn modulates the expression of stress-sensitive genes to epigenetic mechanisms. “So you completely reprogramme these neurons,” noted Professor Baram. “These are likely not the only neurons that are reprogrammed, but they are the ones that are programmed very early in life. Clearly, there are epigenetic changes later in life within neurons in the hippocampus, the prefrontal cortex and other important brain regions.”

Taken as a whole, one can see that a chain of events takes place from aberrant early-life experience (e.g. fragmented care), to stress, to altered connectivity in stress-sensitive brain regions (or changes in synapse number), which ultimately translates to height-

ened or diminished sensitivity to future stress in later life.

“Most emotional disorders are stress sensitive, particularly depression, anxiety and posttraumatic stress disorder – so this really provides, for the first time, description of a complete mechanism from early-life experiences (such as stress) to emotional outcome.”

Crucially, if this mechanistic pathway is taken into consideration, then it opens up potential avenues for early intervention. But how long is the window to treat those at risk, i.e. before influences initiate the proposed ‘reprogramming’ process in the brain? In the ex- “Most emotional disorders tensive Romanian orphan study are stress sensitive … so this really provides,

by Nelson, Fox and Zeanah,1 for the first time, among other works, it has been description of a complete proposed that up until the age mechanism from earlyof two, children will be able to life experiences (such recover much better from earlyas stress) to emotional life environmental stressors. outcome.”

“I would like to consider T allie Z. Baram that two years may not necessarily be the case, or at least that it depends on the degree of the deprivation – which those particular children suffered Funded by the NIMH, the terribly,” said Professor Baram. notion of fragmentation and “In rodent models we are able unpredictability of maternal to very effectively intervene signals to the developing brain early on in life, and beyond the as an important predictor of early-life stress period, but are emotional outcome of children less successful when we try to is being studied. Specifically, intervene during adulthood.” fragmentation and consistStaying on the topic of ency of maternal mood and animal work, Professor Baram heartrate patterns – both stressed that rodent analogues parameters that might be are very fitting in this kind of sensed by the foetus – have work, with principles being been assessed all the way from very similar to that of humans. 15-weeks of foetal growth.

“For example the CRH [Cor“Children exposed to varticotropin releasing factor] ied patterns of maternal signal peptide, one of our focuses, is during foetal life, and to differidentical in humans and roent patterns of maternal care dents,” she noted. “It is differpostnatally, were followed-up ent in pigs, cows and sheep, for in terms of their emotional example, but both the actual outcomes and developmenmolecule, the actual regulation tal intelligence outcomes,” – everything – is similar in described Professor Baram. rodents and humans.”

“Early results at the age of one Professor Baram continued, and two years, and now at 9, 10 describing her recent coland 11, suggest that these patlaborative work with humans. terns and their consistency and

fragmentation are important.”

The human work is being achieved via sophisticated imaging such as diffusion tracer imaging, and functional MRI – which reveals the connectivity, functional integrity and communication pathways between important brain structures.

“We are doing this work parallel to rodents, where we can do the same type of imaging using really high-powered MRIs,” said Professor Baram.

In closing, Professor Baram emphasised that, before we can really begin to think about tangible interventions, the first question left to answer would be to what degree a rodent’s principles and mechanisms reflect the situation in children?

She delved deeper: “For that purpose, these types of analyses allow you to make some hopefully fairly strong inferences.

These are things that are ongoing, and I think if we establish indeed what principles are common then the question is can we use intervention studies from rodents in children?”

References 1. Nelson CA, Fox NA, and Zeanah CH. Romania’s Abandoned Children: Deprivation, Brain Development and the Struggle for Recovery. Harvard University Press. 2014. ISBN 9780674724709 and 26079 (e-book) Further reading 1. Baram et al., AJP 2012 2. Korosi et al., J Neurosci 2010.

3. Gunn et al, J Neurosci 2013.

4 ECNP Daily News Saturday

www.ecnp.eu

EDUCATIONAL

E.04: Anxiety disorders: from new targets to new treatments Elicium 1 Monday 09:00–10:40

Anxiety disorders: A rethink of approaches and targets

A “If people are very ill, they may initially opt for one particular therapy … [but] maintaining treatment can become an issue, especially with side effects.”

Nic van der Wee

nxiety disorders are amongst those with the greatest prevalence, most striking socio-economic burden and tend to have a chronic or recurrent course.

Meta-analyses demonstrate only moderate numbers with full remission, many of whom will relapse and experience side effects, often leading to poor medication compliance or discontinuation. Guidelines for treating anxiety disorders with pharmacotherapy and psychotherapy are formulated on the basis of evidence from clinical trials,1 however limited efficacy, effectiveness and tolerability of current pharmacotherapies means there is an unmet need for new treatment targets and approaches.2 The future perspectives for anxiety disorder treatment will be critically assessed in an educational session held on Monday morning, in which the need for new targets will be of particular focus. “The session is about where we are in the pharmacotherapy

of anxiety at the moment, and what could be row down the therapeutics to those that will the way forward,” session speaker Nic van be effective on/in particular individuals.” der Wee (Leiden University Medical Center, Expanding on this, he touched upon the Netherlands) told ECNP Daily News. today’s ‘holy grail’, the biomarker – a concept “It definitely involves psychotherapy and of huge interest thanks to the possibilities of pharmacotherapy coming together, and also stratifying patient subpopulations, as well as looking into cognitive enhancement.” both tracking drug responses and predictDiscussing why there may be differences ing drug efficacy. Professor van der Wee between what clinicians and patients conoffered a cautiously optimistic outlook on sider to be essential properties for an ‘ideal’ this approach to psychiatric disease in the drug for the treatment of anxiety disorders, real world: “The issue with biomarkers is that Professor van der Wee commented: “If peo- we have many studies showing biomarkers in ple are very ill, they may initially opt for one samples that are not replicated in cohorts of particular therapy to reduce their anxiety, patients.” but when it becomes manageable, the side He continued: “We most certainly need effects may become more of an issue. In this to investigate biomarkers to improve our case maintaining treatment can become an understanding of the underlying psychopissue, especially with side effects like sexual harmacology of diseases, especially if they are dysfunction. combined with clinical markers, like trauma “If observer-rated scales alone are used or abuse.” However, he added that in a field of for drug effectiveness assessments, without high expectations where outcomes can differ consideration of the patient-reported hugely from one disorder to another, there is outcomes, there may be huge discrepancies a pragmatic clinical perspective – i.e. the need between the verdict of physician and that of the patient.” He added that this also holds “I do believe that by better stratifying true whether the non-response of a drug our patients, we can narrow down treatment is actually valid, as in some cases the therapeutics to those that will be incorrect dosing and treatment duration, effective on/in particular individuals.” or poor patient compliance are to blame: “We need to look into real-world efficacy of Nic van der Wee treatment.”

With regards to maintenance treatment, it need not take the same form as initial to balance biomarkers’ predictive capabilities treatment, and currently a multidisciplinary with other factors, for instance how much approach is recommended for treatment they cost, and how invasive are they. of anxiety disorders: data has shown that “I think that genetic biomarkers would be combination therapy (pharmacotherapy the most relevant in pharmacogenetics – just and psychotherapy) is most effective.3 If figuring out whether someone was a rapid the patient has more symptoms, they can or poor metaboliser of a drug would have a be shifted to pharmacotherapy from CBT. massive effect on how you would arrange the The current multidisciplinary guidelines in pharmacotherapy,” said Professor van der the Netherlands recommends that the first Wee. “Epigenetic biomarkers may be more course of treatment, in non-complex cases, informative than classic genome-wide testing should be psychotherapy. Whilst CBT can for patients, thus this concept is very interestbe highly effective, it brings its own potential ing for research, but we are not sure yet how complications as Professor van der Wee it can be applied treatment-wise.” pointed out: “There may be issues with CTB In his closing remarks, Professor van der in terms of availability and if someone is in Wee turned to drug repurposing as a particuremission from pharmacotherapy there is not larly promising solution in anxiety disorders, much left to do CBT on.” noting that by re-evaluating and re-charHe added: “It’s about balancing the pharacterising potential, hitherto-undiscovered macological and psychological effects – they properties of clinically-used agents, there may are both very important with regards to initial be great scope for potential anxiolytic use. treatment and maintenance, but sustainability References 1. Baldwin DS, et al. Evidence-based guidelines for the is important too.” pharmacological treatment of anxiety disorders: recommenContinuing with this patient-centric dations from the British Association for Psychopharmacoltactic, Professor van der Wee went on: “As ogy. Journal of psychopharmacology. 2005;19:567-596. for personalised medicine, it’s a matter of 2. Millan MJ, et al. Learning from the past and looking to the debate: is there one drug for one patient, and future: Emerging perspectives for improving the treatment of different drug for another? Whilst that might psychiatric disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharbe too simplistic an approach, because we see macology. 2015;5:599-656. involvement at different levels – biologically 3. Cuijpers P Combined pharmacotherapy and psychotheraas well as psychologically – I do believe that py in the treatment of mild to moderate major depression? by better stratifying our patients, we can nar- JAMA psychiatry. 2014;71:747-748.

ECNP Daily News Saturday 5

www.ecnp-congress.eu

CLINICAL TREATMENT

S.01: TNM symposium – Adult separation anxiety disorder Elicium 2 Saturday 16:50–18:30

Unravelling the genetic nature of anxiety disorders:

Towards individualised diagnosis and therapies

K

atharina Domschke is a professor of Psychiatry at the University of Wuerzburg, Germany, with a clinical focus on depression, anxiety disorders, stress-related disorders, obsessive-compulsive disorders and eating disorders. To that end, Professor Domschke will be sharing her experience this afternoon, with a stimulating talk on the genetic dissection of anxiety disorders, posing the question of whether ‘separation anxiety disorder’ can be distinguished.

Speaking to ECNP Daily News, she began by illustrating the necessity for research in biological psychiatry, saying: “Clinical genetic studies propose a genetic influence of 30-60% for the pathogenesis of anxiety disorders, and there is a complex genetic aetiology.”

Determining genetic and environmental risk factors is at the core of diagnosis and treatment of psychiatric disorders. Describing the techniques utilised leading up to their group’s more recent findings, Professor Domschke expanded said: “In order to work out which chromosomal loci and which genes are involved, we need to study the molecular genetics. This involves performing linkage, association and genome-wide association studies to measure the effects of risk genes.”

Since 2000, Professor Domschke has been actively involved in the field of biological psychiatric research with a strong focus on the epigenetics, imaging genetics and pharmacogenetics of anxiety, and her research group has been pivotal in revealing associations of different genetic variants with anxiety disorders, for example G protein-coupled receptor RSG2,1,2; different polymorphisms in genes encoding catecholamine catabolism enzymes catechol-O-methyltransferase,3 and monoamine oxidase A4; various polymorphisms of the serotonin receptor 1A gene5; as well as modulation of the gene for neuropeptide, oxytocin6, to mention but a few.

However, it was the discovery of an association between genetic variations in the neuropeptide S receptor gene (which Professor Domschke affectionately refers to as “their baby”) with panic disorder that captured attention of those studying the pathogenesis of anxiety disorders. A huge focus in Professor Domschke’s research group is finding a functional role for this neuropeptide. A functional polymorphism in the NPSR1 gene has been linked to aberrant cortico-limbic interactions7; and NPSR1 A/T polymorphism is associated with anxiety-, depression- and activity-related traits, various disorders and suicidal behaviour.8 Professor Domschke described one of

“The waxing and waning of DNA methylation may be the link between genes and the environment.”

Katharina Domschke

the most fashionable research developments in this area: epigenetics. Epigenetics encompasses mechanisms that regulate gene expression without actually altering the genotype – instead comprising gene modulation such as methylation and demethylation. She explained: “The waxing and waning of DNA methylation may be the link between genes and the environment; and these could even be transmitted transgenerationally.”

Professor Domschke continued: “Our group was the first to show GAD1 methylation’s association with panic disorder; we showed that hypomethylation is associated with both panic disorder and a high number of negative life events.9 New data is now showing psychotherReferences 1. Hommers L, Raab A, Bohl A, Weber H, Scholz CJ, Erhardt A, et al. MicroRNA hsa-miR-4717-5p regulates RGS2 and may be a risk factor for anxiety-related traits. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

2015;168B(4):296-306. Epub 2015/04/08.

2. Hohoff C, Weber H, Richter J, K, Zwanzger PM, Ohrmann P, et al. RGS2 genetic variation: association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2015;168B(3):211-22. Epub 2015/03/06.

3. Domschke K, Winter B, Gajewska A, Unterecker S, Warrings B, Dlugos A, et al. Multilevel impact of the do-

pamine system on the emotion-potentiated startle reflex. Psychopharmacology. 2015;232(11):1983-93.

Epub 2014/12/17.

4. Reif A, Richter J, Straube B, Hofler M, Lueken U, Gloster AT, et al. MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. Molecular psychiatry. 2014;19(1):122-8. Epub 2013/01/16.

5. Straube B, Reif A, Richter J, Lueken U, Weber H, Arolt V, et al.

The functional -1019C/G HTR1A polymorphism and mechanisms of fear. Translational psychiatry.

2014;4:e490. Epub 2014/12/17.

6. Ziegler C, Dannlowski U, Brauer D, Stevens S, Laeger I, Wittmann H, et al. Oxytocin receptor gene methylation: converging multilevel evidence for a role in social anxiety.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2015;40(6):1528-38. Epub

apy as having an effect on DNA methylation, demonstrating its biological effect.”

The measurement of genetic and environmental biomarkers of mental disorders and treatment response is in its infancy, and large genetic studies in concert with translational research are essential to improve the understanding and predictability of mental disorders. Professor Domschke gave an example of how genetic and environmental risk factors may interact to influence the propensity for development of anxiety disorders: “There is a close aetiological and epidemiological connection between separation anxiety disorder and panic disorder. They are both highly heritable … and it has been suggested that this link may be conferred via CO2 sensitivity – an endophenotype common to both disorders.”10 Looking to the future, Professor Domschke went on to describe her three main research goals: “First is the detection of early genetic risk factors and epidemiology using biomarkers as preventative measures,” she said, adding: “At the moment, these biomarkers are largely universal selective measures such as neuropsychiatric tests and anxiety measures, but ideally we would like to see more specific biomarkers so those at high risk can be targeted early.

“Second is to develop an individuallytailored therapeutic approach to therapy – for example using a panel of about 10 risk factors as biomarkers in concert with functional brain imaging, to measure and compare responses to drug therapy.

“Finally is the development of new and innovative approaches to patient treatment, for example an intranasal neuropeptide S treatment for humans. This has been shown to decrease anxiety in mice and rats by researchers at the University of Regensburg [Germany] and the Max Planck Institute.”11, 12 These studies on (epi)gene-environment interactions will help to elucidate maladaptation to separation life events with the ultimate goal of developing novel, individualised approaches to diagnosis and therapies.

2015/01/08.

7. Neufang S, Geiger MJ, Homola GA, Mahr M, Akhrif A, Nowak J, et al. Modulation of prefrontal functioning in attention systems by NPSR1 gene variation. NeuroImage. 2015;114:199-206. Epub 2015/04/07.

8. Laas K, Reif A, Kiive E, Domschke K, Lesch KP, Veidebaum T, et al. A functional NPSR1 gene variant and environment shape personality and impulsive action: a longitudinal study.

Journal of psychopharmacology (Oxford, England). 2014;28(3):22736. Epub 2013/01/18.

9. Domschke K, Tidow N, Schrempf M, Schwarte K, Klauke B, Reif A, et al. Epigenetic signature of panic disorder: a role of glutamate decarboxylase 1 (GAD1) DNA hypomethylation? Progress in neuropsychopharmacology & biological psychiatry. 2013;46:189-96. Epub 2013/08/03.

10. Battaglia M, Ogliari A, D’Amato

F, Kinkead R. Early-life risk factors for panic and separation anxiety disorder: insights and outstanding questions arising from human and animal studies of CO2 sensitivity.

Neuroscience and biobehavioral reviews. 2014;46 Pt 3:455-64. Epub 2014/05/06.

11. Dine J, Ionescu IA, Avrabos C, Yen YC, Holsboer F, Landgraf R, et al. Intranasally applied neuropeptide S shifts a high-anxiety electrophysiological endophenotype in the ventral hippocampus towards a “normal”-anxiety one. PloS one. 2015;10(4):e0120272.

Epub 2015/04/02.

12. Lukas M, Neumann ID. Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects. Neuropharmacology. 2012;62(1):398-405. Epub 2011/08/30

6 ECNP Daily News Saturday

www.ecnp.eu

THE 28TH ECNP CONGRESS

Highlights from Amsterdam

This year’s congress highlights

P

lumbing the depths of many key research topics, the scientific programme of the 28th ECNP Congress boasts a Keynote lecture by internationallyacclaimed primatologist Frans BM de Waal this evening, and thereafter is punctuated by six plenary lectures by well-known names at the leading edge of neuropsychopharmacology. To share his perspectives on the congress highlights, Wim van den Brink (Academic Medical Centre Amsterdam, the Netherlands) spoke to ECNP Daily News about the topics that feature most prominently this year.

Professor de Waal’s Keynote lecture ‘Prosocial primates: cooperation and empathy’ (page 2) provides the centrepiece to the Keynote Session that takes place this evening (18:45– 20:00, Auditorium). Publishing prominently both in scientific journals and in popular work, Professor de Waal’s first book, Chimpanzee Politics, compares the power relationships within chimpanzee social groups with those of human politicians.

“Frans de Waal will talk on the issue of cooperation and empathy,” explained Professor van den Brink. “He will explain how this works among apes and what we can learn from them about human behaviour.

He has worked for many years with chimpanzees, and he really has very interesting things to say. It will be a fantastic lecture.”

Sunday morning follows with the first plenary lecture on the neural correlates of chronic early life stress, presented by Tallie Z Baram (11:15–12:00, Auditorium). “Everybody knows that early-life stress is very important in almost all psychiatric disorders,” said Professor van den Brink. “And this translational point of view will be interesting. I think there is a lot of speculation about what is happening in the brain in early-life stress, and we don’t know enough about it.”

Going on to highlight Francesc Artigas’s Sunday afternoon plenary lecture focused on the development of more potent and effective antidepressants (14:00–14:45, Auditorium), Professor van den Brink stressed the importance of the issue, demonstrated by the fact that classic antidepressants can take between two and eight weeks to bring about any noticeable effect.

Then, drawing attention to the plenary lecture of Brain Prize winner Trevor Robbins, who will talk on the topic of impulsivity and compulsivity (Tuesday, 11:15–12:00, Auditorium), Professor van den Brink continued: “These were concepts that, for many years, were used as opposing poles of a dimension. Now we understand them as being more continuations of the same thing. In a lot of patients we see that impulsivity often co-occurs with or develops into compulsivity – we see this in OCD as well as addiction.

This is a really an important

new insight.”

The role of early life stress and childhood disorders that persist into adult psychiatric disorders is certainly a prominent theme at this year’s congress. “Unlike most other disorders and diseases in humans, psychiatric disorders start earlier in life,” explained Professor van den Brink. “This is partly why they create such a burden to society.”

“We have sessions on disruptive behavioural disorders and ADHD, with the latter being a much debated issue among professionals, the lay public and even politicians; although there is no doubt that many children that start off with a serious form of ADHD will develop all kinds of other mental disorders later on.

“This is also interesting because there was an announcement that scientologists will be protesting outside the conference this year. They are against all forms of psychopharmacology, but they particularly focus on the pharmacological treat-

“Frans de Waal will talk on the issue of cooperation and empathy. He will explain how this works among apes and what we can learn from them about human behaviour.”

Wim van den Brink

“In a lot of patients we see that impulsivity often cooccurs with or develops into compulsivity…This is a really an important new insight.”

Wim van den Brink

ment of children with ADHD, despite this year’s Lancet report that untreated children with ADHD have a much higher probability of injuries and emergency room visits than treated children with ADHD.[1] We think, therefore, it needs a lot of attention.”

Professor van den Brink also drew special attention to the plenary lecture of Ned Kalin on anxious temperament (Tuesday, 14:00–14:45, Auditorium), which seems closely connected to what is now called adult separation disorder; an issue that is discussed during the TNM session on Saturday afternoon (16:50–18:30, Elicium 2). The emergence of the disorder, previously held to occur only in children, has prompted work looking at intervention and prevention.

“In terms of medication, there is a lot of interest in oxytocin,” explained Professor van den Brink. “This is the bonding hormone that is also being used now in schizophrenia and autism – these are disorders where bonding and interaction is important. We will have the first findings in the use of oxytocin presented too [‘Oxytocin in schizophrenia: new research findings’; Monday 09:00–10:40, Auditorium].”

Encouraging delegates to pay a visit to all of the plenary lectures, Professor van den Brink spoke of the remaining two, ‘The role of motivation and reward in mental disorders’ by Andreas Heinz (Monday, 11:15–12:00, Auditorium) and ‘Is it time for immunopsychiatry?’ by Marion Leboyer (Monday, 14:00–14:45, Auditorium): “Together with many other sessions on many different topics and covering almost all psychiatric disorders, these plenary lectures will be an exciting experience,” he concluded.

References 1. Dalsgaard S et al. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015;2(8):702-9.

8 ECNP Daily News Saturday

www.ecnp.eu

CLINICAL RESEARCH

S.02: Biomarkers in the clinic – are we there yet? Forum Saturday 16:50–18:40

Still a long road for clinical biomarkers?

A

session that will dissect contemporary perspectives on clinical biomarkers for ADHD, psychosis, depression and other disorders will take place this afternoon, with the underlying question being ‘Are we there yet?’.

Tackling the topic of potential biomarkers for psychosis prediction during the session will be Paolo Fusar-Poli (Department of Psychosis Studies, King’s College London, UK), who will focus on the clinical relevance of stratifying people at risk for psychosis, in order to prevent the onset of this severe and disabling psychiatric condition.

“First of all I must stress that there are no “There is an urgent need for external validation such biomarkers validated in clinical psychia[of biomarkers], and try,” Dr Fusar-Poli told ECNP Daily News. this is why the field is “There are some suggestions, but findings are now trying to create somewhat conflicting, despite meta-analyses,” international databases he said. and international Despite the lack of validated psychosis projects to try and biomarkers, Dr Fusar-Poli noted that the field promote replication and is alive and well in its search for candidates: “While those methods will employ validation.”

“The field is extending from neurobiology, validation techniques … no external Paolo Fusar-Poli and by that I am thinking of structural grey validation of the suggested classifier matter alterations, white matter alterahas been properly done. So we don’t tions and functional alterations, and also know whether a neuroimaging classineurochemical alterations, mostly including fier developed in, say, Munich or Bern is valid dopamine and glutamate. Neurocognition is in London, for example. Hence there is an the second area that has attempted to identify urgent need for external validation, and this biomarkers to predict the onset of psychosis, is why the field is now trying to create interand then there is the clinical field – basically national databases and international projects trying to identify clinical predictors of longito try and promote replication and validation tudinal transition to psychosis. of biomarkers across different consortiums.”

“Then obviously we have environmenDr Fusar-Poli also noted that standardital markers such as trauma or exposure to sation of clinical assessment would help miniprevious life events. They may not qualify as mise differences in the definition of patients standard biomarkers, so if we want to speak at risk of psychosis. “This is something we of neurobiological markers, I think there the are trying to address, collaborating with the evidence is still only preliminary.”

Hans Boström National Institutes of Health [NIH] in the US, As Dr Fusar-Poli described, the field is now moving towards integrating different ideas, becoming almost ‘agnostic’ as to what kind of marker is better suited to predict the onset of psychosis. “We are trying to combine these different measures – not just neurobiology, but also environmental and personal markers, as well as clinical markers and neurocognitive markers to build a predictive model for the outcome, using sophisticated methods.”

Comparison between studies is a particular challenge when analysing the potential of a candidate biomarkers, in part due to differences in patient demographics, imaging modalities, evaluation methods and other factors.[1] As such, consistency across different countries, samples and high-risk services is still highly questionable, as Dr Fusar-Poli detailed: “If you think of the best approaches identified with, for example, machinelearning methods – grey matter alterations predicting the onset of psychosis – they have been mostly investigated in one or two sites.

moving towards specific projects to merge data, and standardise a tool to assess people at risk for psychosis.”

On that topic, Dr Fusar-Poli highlighted that there are three, large, international studies underway dedicated to stratifying psychosis risk, and prediction of onset. These trials are split between the UK, Germany and the US, with Dr Fusar-Poli being involved in the London-based PSYSCAN trial.[2] Commenting on a core future goal, he concluded: “It is trying to merge these databases in order to achieve harmonisation of clinical assessment, and replication and validation of biomarkers. Most of them will be based on machine-learning codes, combining the different elements: so not just neuroimaging, but also neurocognition, clinical symptoms, and environmental predictors as well.”

‘Digital health biomarkers’ for ADHD

Also speaking during the session will be Hans Boström (Medical Director, Qbtech AB, Stockholm, Sweden) who will discuss the clinical implementation of neurobiological measures in the management of ADHD. Since 2010, Dr Boström has been Medical Director at Qbtech – a company that started on the back of an innovative update to traditional continuous performance tests (CPTs) for ADHD, whereby a camera was incorporated to measure activity of those undertaking the test. This added functionality was able to focus on the hyperactivity component of ADHD, which so many other CPTs under-examine. “Most of todays’ CPTs do not include a dedicated hyperactivity component,” he told ECNP Daily News. “Instead they basically calculate it from an algorithm.”

Once this new, improved ‘QbTest’ was realised, the company began to focus on what could be done to develop the technology further, with hopes to implement a useful testing modality in the clinic.

Inevitably, questions also arose from peers as to the validity and clinical applicability of the test, particularly in terms of how useful it would be when compared to DSM-V criteria for diagnosis of ADHD. “What we are trying to do now is to challenge that,” said Dr Boström.

“What we initially focused on was documenting how the test could differentiate between normative people, and those with ADHD. By doing that you first have to sample the normative data, which we have on approximately 1,300 subjects, ages 6 to 60, and then when you measure someone in whom you suspect ADHD, you will get a score – we call it a Q-score – which is the difference in standard deviation, more or less, to what is normative. When you have 1-2 standard de-

ECNP Daily News Saturday 9

www.ecnp-congress.eu

viations from norm, there is a higher likelihood that you have problems that are associated with ADHD.” This evaluative phase showed that the QbTest had approximately 90% sensitivity and specificity – a result which earned it an informal classification as a biomarker. “I think in a way it we could call it a ‘digital health biomarker’,” noted Dr Boström.

Despite this result, he noted that in a clinical setting, ‘normative’ patients rarely come through the door. “Rather you have people with a lot of comorbidities, which could be depression, bipolar disease – anything like that. So what we are struggling with right now, and what I will talk about, is differential diagnosis.

“How can a test like this differentiate typical ADHD from typical borderline or bipolar disorder or depression? We are developing specific algorithms that look at several parameters together. It is not as advanced as an artificial neuronal network, rather you measure different types of response profiles, and then the test compares the test profile from specific patient groups, and then you can post the likelihood of whether you belong to the ADHD group or not.”

Dr Boström will also touch upon endophenotypes – specifically recounting a study looking at healthy siblings of ADHD sufferers. “What we could see there interestingly was that hyperactivity, for example, was increased in the healthy siblings, although they did not have the disease,” he said

“That shows that hyperactivity, as we measure it, could be an endophenotype of ADHD. That you have the vulnerability for the disease, but for whatever reason, you haven’t got it.”

Another area sparking interest for Dr Boström is the ability to test the efficacy of a medicine. With present-day methods being largely based on asking patients how they feel after taking medications, Dr Boström argued that this ‘arbitrary’ evaluation could really benefit from QbTest’s more objective assessment. “What we can do is measure the profile before treatment, at the first dose, and then after three and six months,” he said. “And then we can see quite early if there is a response to the medicine.

“This is more important today, because we have a lot of new drugs coming in to the field. Before it was mostly methylphenidate, but now you also have dexamphetamine, and others such as atomoxetine.

QbTest is very objective way to show if a medicine works or not, and we have witnessed both over- and under-prescription of drugs, so the tool can be quite effective in pitching the level of adequate treatment.”

Looking to the future, Dr Boström noted that collaboration was key in order to better implement this kind of objective testing in the clinic. By furthering data collection, and by merging that brain data with clinical assessment, the combination could bestow more diagnostic power. “The interesting aspect of CPTs, compared to MRI and other very advanced

technology, is that it is quite easy to do in the clinic,” he said.

“But ultimately, we want to know what the test adds in terms of clinical value? If you install test equipment, do you improve the time to diagnosis in that clinic? Do you improve the way you use medicine? We also have a lot of studies in that arena. “ In his closing remarks, Dr Boström framed the importance of this digital health corner of the broader biomarker arena, first underlining that, due to the test’s simplicity, use of the test in the home could be an attainable goal in the near future. “I think it will be a new era for CPT,” he said. “It has been looked at over the shoulder somewhat, at least from a lot of psychologists who rely on long interviews for diagnosis.”

He concluded “It is also very important as a takehome message that it is not a standalone test. You have to use this objective test in combination with a clinical impression, and the rating scale. If you have those three in place, you have a much better view of ADHD.” References 1. Kambeitz J, et al. Detecting Neuroimaging Biomarkers for Schizophrenia: A Meta-Analysis of Multivariate Pattern Recognition Studies.

Neuropsychopharmacology (2015), 1–10. doi:10.1038/npp.2015.22 2. PSYSCAN – Translating neuroimaging findings from research into clinical practice. http://ec.europa.eu/ [Accessed August 2015] 3. Qbtech. How QbTest Works. https://www.qbtech.com/qbtest.html [Accessed August 2015]

ECNP Journal: European Neuropsychopharmacology

Behind the scenes at European Neuropsychopharmacology

J

aanus Harro (University of Tartu, and Psychiatry Clinic of the North Estonia Regional Hospital, Tallinn, Estonia) is Field Editor of European Neuropsychopharmacology, the official journal of ECNP, which encompasses clinical and basic research in the field. He also oversees congress abstract publication, as well as being a member of the ECNP Communication Committee, and of the Workshop Committee that oversees the annual Nice Workshop, next taking place 17-20 March, 2016.

As the final reviewer of all submitted abstracts – which have amounted to “ECNP has a well-established over 1,000 over the past peer review system for the few years – Professor abstracts. Most often, each has Harro gave a little insight been rated and commented on into his position, and the by three reviewers, but this can process of abstract selecrange from two to six.” tion, in an interview with ECNP Daily News: “ECNP Jaanus Harro has a well-established

peer review system for the abstracts,” he said. “Most often, each has been rated and commented on by three reviewers, but this can range from two to six. I do read all abstracts to note technical issues.

“When the Scientific

Programme Committee or the Workshop Committee respectively set up priorities or require other input, such as a proposal for an award committee, then I help to incorporate these suggestions into the decision-making process and provide draft proposals.

All this is based mostly on the reviewer’s suggestions – which are the oxygen for the process – but it may now and then be necessary to balance these across panels.”

Speaking of the challenges of the role in terms of balancing content, taking into account shifting themes whilst maintaining the breadth that the journal’s name spans, he explained that the eventual balance of topics of publication necessarily reflect the scope and coverage of submitted work: “We place emphasis on quality,” he stressed, adding: “A challenge is always there if the reviewers

have wildly different opinions of an abstract. For the two most recent congresses, we have had to impose a limit on the number of abstracts accepted, because the number of submissions has increased but there are space constraints at the venue.”

Speaking of Jan van Ree, the founding Editor and former Editor-in-Chief of European Neuropsychopharmacology, Professor Harro said: “He stands out in particular as the person who established the robust and efficient system that we have. He personally instructed me on how to begin and taught me the tricks of the trade. I hope the standard he achieved has been kept, and that he is satisfied with the journal.”

Read the latest from European Neuropsychopharmacology at www.europeanneuropsycho pharmacology.com

10 ECNP Daily News Saturday

www.ecnp.eu

PRECLINICAL RESEARCH

S.04: Merging mouse and human data on the role of PolySia-NCAM Emerald Saturday 16:50–18:30

Cortical plasticity mediators in schizophrenia

J

uan Nacher (University of Valencia, neighbourhood.”

Spain) has worked extensively on the In the cerebral cortex, most PolySia is role of adhesion molecule NCAM and its found on certain interneurons, which sets “We looked at polysialylated form, PolySia-NCAM, in the these apart from other interneurons in terms the brains of schizophrenic structural plasticity of interneurons in health of structure and connectivity. More specifipatients, and we and psychiatric illness. This afternoon, he cally, they demonstrate reduced arborisation found that the opens a preclinical research symposium dedi- and fewer synaptic connections. expression of cated to the molecule and the part it plays Going back to the beginnings of his [PolySia-NCAM] during neurodevelopment and schizophrenia. research in PolySia-NCAM, Dr Nacher was altered in Structural remodelling, or plasticity, is a recalled: “Because this is a molecule that is some regions of critical facet of cognitive process and the dyrelated to plasticity, we started to ask whether namic response of brain structures to stimuli. it could be modulated by some molecules that the prefrontal cortex.”

The mediators of plasticity in both excitaare very important to psychiatric diseases, tory and inhibitory neurons are of particular like dopamine and serotonin. In fact, the Juan Nacher interest to illuminating the mechanisms expression of this molecule is modulated by underlying psychiatric disorders, and indeed these monoamines. inhibitory neuron remodelling has been “So we then looked at the brains of demonstrated after chronic stress.1 schizophrenic patients, and we found that PolySia-NCAM has been implicated as the expression of this molecule was altered in a plasticity mediator by its association with some regions of the prefrontal cortex, which a subpopulation of cortical interneurons, as is a critical region in schizophrenia. These Dr Nacher explained in conversation with changes in this molecule, from NCAM to ECNP Daily News: “NCAM has the ability PolySia-NCAM, occur in parallel to changes to incorporate long chains of sugars that in the expression of molecules related to make NCAM anti-adhesive. So when NCAM inhibitory neurons in the prefrontal cortex.” is polysialylated, it cannot bind to another Interestingly, both NCAM and the enNCAM molecule of another cell. zymes that bond the PolySia sugar to NCAM “When this occurs, it is easier for the have been identified as candidate genes in neuron to change its structure, or to even schizophrenia in certain genetic studies. allow some processes such as migration or Recent work by Gianfranco Spalletta, who will synaptogenesis to happen. also be speaking during the This is very important symposium, has evidenced “We have worked with during the development the correlation of clinical antipsychotics and antiof the CNS, but we have and brain structures with depressants; both of these found that this also ocserum NCAM and PolySia have a strong impact on curs during adulthood in levels in schizophrenia.2 PolySia-NCAM, and at the certain regions. When the Dr Nacher’s group, same time reorganise the PolySia sugar is present along with others, have inhibitory neurons in the the neurons are apparalso shown in mouse that prefrontal cortex.” ently more able to change altering genes involved in their structure or even to NCAM and its polysialylaJuan Nacher become isolated from the tion during development

results in dramatic changes in cortical inhibitory networks. Moreover, they have demonstrated alterations in these cortical inhibitory neurons and in the expression of PolySiaNCAM in animal models of schizophrenia.

Current schizophrenia medications have been shown to significantly influence NCAM and PolySia-NCAM, noted Dr Nacher: “We have worked with antipsychotics and anti-depressants; both of these have a strong impact on PolySia-NCAM, and at the same time reorganise the inhibitory neurons in the prefrontal cortex.”

But a growing body of knowledge regarding the mechanisms of plasticity involved in schizophrenia is argument enough for the identification of therapeutic molecules that could reverse developmental aberrations in NCAM. Indeed, this forms one of the directives of the ERA-NET NEURON consortium, out of which this symposium arose.3 “We don’t have definitive results on that yet,” explained Dr Nacher. “But this is the direction we are working in. There are several peptides that can mimic PolySia and some that mimic NCAM, so we can play around with these to try to reverse the alterations that these molecules have during development.”

Dr Nacher joins other speakers in a symposium on both mouse and human data on the role of PolySiaNCAM in neurodevelopment and schizophrenia, this afternoon between 16:50 and 18:30 in the Emerald room.

References 1 Nacher J et al. Structural plasticity of interneurons in the adult brain: role of PSA-NCAM and implications for psychiatric disorders. Neurochem Res. 2013 Jun;38(6):1122-33.

2 Spalletta G et al. Clinical and brain structural correlates of NCAM and polysialic acid serum levels in schizophrenia.

ECNP Congress 2015 (retrieved from www.ecnp-congress. eu/programme/Programme_overview.aspx) 3 ERA-NET NEURON consortium. www.neuron-eranet.eu/ index.php

Don’t miss…

This year’s series of Brainstorming Sessions 07:45 Sunday-Tuesday

ECNP

This year’s series of Brainstorming Sessions will begin tomorrow at 07:45. These are small, focused sessions organised by ECNP members on a topic of their choice. The organiser of the session and a second expert in that specific field of interest will initiate the discussion.

12 ECNP Daily News Saturday

www.ecnp.eu

PRECLINICAL RESEARCH

S.08: MicroRNAs: leading actors in the scenario of mood disorders Emerald room Sunday 09:00–10:40

M

ajor Depressive Disorder (MDD) is a devastating illness that significantly affects family and personal relationships, sleeping and eating habits, and work and school life. Its impact on functioning and wellbeing has been compared to that of chronic medical conditions like diabetes mellitus.1 The most common drugs used to treat MDD are selective serotonin reuptake inhibitors (SSRIs), but the exact mechanism of SSRIs in relieving depression is not fully elucidated: remission from depression takes several weeks, despite rapid onset of serotonin reuptake inhibition, pointing to neuronal rewiring and synaptogenesis or neurogenesis.

ECNP Daily News spoke with Noam Shomron (Tel Aviv University, Israel) prior to his talk ‘Gene and microRNA expression in the mode of action of treatments for major depression’, where he will show his pioneering study into SSRI responsivity. “More than 30% of patients with MDD do not respond well to first-line treatment with SSRIs,” he began. “We want to assist in the trial and error approach to selecting the right drug and the right dose. We used a surrogate cell – LCL (lymphoblastoid cell lines), which are immortal lymphocytes lines, transformed with Epstein-Barr virus,2 and exposed them for a short duration (three days) to SSRI paroxetine.

“Previous studies have looked at polymorphisms and their associations with drug responses and have focused on the serotonin transporter, but none of the studies were reproducible. Our results suggest that there are other measures that can be used to evaluate drug dose. We noted a marked correlation between cell growth and differential responses to SSRI. We then took the extreme cases – the cells that had either grown very slowly (or been damaged by the SSRIs), and those that had proliferated really well and we compared their miRNA.” Using genome-wide miRNA expression to profile the LCL upon exposure to SSRIs, Dr Shomron’s approach was to look at these cells with a very wide scope. The results showed 61 References 1. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Archives of general psychiatry. 1995;52(1):11-9.

Epub 1995/01/01.

2. Rajesh D, Dickerson SJ, Yu J, Brown ME, Thomson JA, Seay NJ. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells.

Blood. 2011;118(7):1797-800. Epub 2011/06/29.

3. Hillenbrand R, Molthagen M, Montag D, Schachner M. The close homologue of the neural adhesion molecule L1 (CHL1): patterns of expression and promotion of neurite outgrowth by heterophilic interactions.

The European journal of neuroscience.

1999;11(3):813-26. Epub 1999/04/02.

“We want to assist in the trial and error approach to selecting the right drug and the right dose.”

Noam Shomron

4. Sakurai K, Migita O, Toru M, Arinami T. An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia.

Molecular psychiatry. 2002;7(4):412-5.

Epub 2002/05/03.

5. Salyakina D, Cukier HN, Lee JM, Sacharow S, Nations LD, Ma D, et al. Copy number variants in extended autism spectrum disorder families reveal candidates potentially involved in autism risk. PloS one. 2011;6(10):e26049. Epub 2011/10/22.

6. Yamanaka H, Kobayashi K, Okubo M, Fukuoka T, Noguchi K. Increase of close homolog of cell adhesion molecule L1 in primary afferent by nerve injury and the contribution to neuropathic pain.

The Journal of comparative neurology. 2011;519(8):1597-615. Epub 2011/04/01.

differentially-expressed genes, none of which were related to serotonin, the serotonin transporter or transcription of serotonin.

Instead, at the top of the list (and six-fold lower in paroxetine sensitive cells) was CHL1, a cell-adhesion protein and close homologue of L1. On the basis of these findings CHL1 was identified as a tentative SSRI sensitivity biomarker.

Dr Shomron continued: “More encouraging still was the discovery that CHL1 was expressed in the brain,3 that it was implicated in both schizophrenia and autism,4,5 and it also was involved in neuronal guidance.6 In animal studies it has been shown that CHL1 is co-expressed with L1 in the dorsal thalamus and this neuronal pathway is implicated in mood control in wild-type mice.7 Furthermore, the CHL1 knockout mouse showed a shift in the axon from thalamus to 7. Wright AG, Demyanenko GP, Powell A, Schachner M, Enriquez-Barreto L, Tran TS, et al. Close homolog of L1 and neuropilin 1 mediate guidance of thalamocortical axons at the ventral telencephalon. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007;27(50):13667-79.

Epub 2007/12/14.

8. Heyden A, Angenstein F, Sallaz M, Seidenbecher C, Montag D. Abnormal axonal guidance and brain anatomy in mouse mutants for the cell recognition molecules close homolog of L1 and NgCAM-related cell adhesion molecule. Neuroscience.

2008;155(1):221-33. Epub 2008/07/01.

9. Clark SL, Adkins DE, Aberg K, Hettema JM, McClay JL, Souza RP, et al.

Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychological medicine.

the visual cortex and altered connectivity in the prefrontal cortex.”8 These data, collected from Dr Shomron’s small study (10 cells, studying gene expression, costing $10,000) was corroborated two years later by a large and costly study carried out by the STAR*D consortium that looked at 1149 DNA samples, and clinical data for 998 MDD patients. The authors also ranked the different polymorphisms, showing five genes possibly involved in mood disorders and to Dr Shomron’s delight, CHL1 was amongst them.9 Galvanised by this data, Dr Shomron repeated these gene expression studies with a longer, 21-day exposure to SSRI paroxetine.

Once again the serotonergic transporter was not involved, but this time neither was CHL1.

Instead the protein ITGB3 – coding for integrin beta-3 – was differentially expressed between the responders and non-responders.10 This gene is found expressed in the hippocampus and frontal cortex and is essential for serotonergic activity,11 and is implicated in autism,12 and early-onset schizophrenia.13 It is known that ITGB3 binds to serotonin transporter,14 but it is unknown is how CHL1 is involved. Dr Shomron postulated that excess CHL1 attracts ITGB3 (thereby competing with the serotonin transporter), which then makes the transporter is less active.

The final question is whether ITGB3 or CHL1 expression can be used as biomarkers for SSRI response biomarkers. The potential value of these miRNAs as tentative SSRI response biomarkers has proven in mice,15 and these findings implicate ITGB3 in the mode of action of SSRI antidepressants providing a novel link between CHL1 and the serotonin transporter. Dr Shomron is currently extending this study in humans, testing whether these miRNAs have predictive responsivity to SSRIs in humans using simple blood test by comparing 100 patients and after treatment.

For now, it is clear that human LCLs are a powerful and cost-effective tool showing great potential as response biomarkers for individualised treatment.

2012;42(6):1151-62. Epub 2011/11/02.

10. Oved K, Morag A, Pasmanik-Chor M, Rehavi M, Shomron N, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Translational psychiatry.

2013;3:e313. Epub 2013/10/17.

11. Ellegood J, Henkelman RM, Lerch JP. Neuroanatomical Assessment of the Integrin beta3 Mouse Model Related to Autism and the Serotonin System Using High Resolution MRI. Frontiers in psychiatry. 2012;3:37. Epub 2012/05/05.

12. Napolioni V, Lombardi F, Sacco R, Curatolo P, Manzi B, Alessandrelli R, et al. Family-based association study of ITGB3 in autism spectrum disorder and its endophenotypes. European journal of human genetics : EJHG. 2011;19(3):3539. Epub 2010/11/26.

13. Wang KS, Liu X, Arana TB, Thompson N, Weisman H, Devargas C, et al.

Genetic association analysis of ITGB3 polymorphisms with age at onset of schizophrenia. Journal of molecular neuroscience : MN. 2013;51(2):446-53.

Epub 2013/07/19.

14. Whyte A, Jessen T, Varney S, Carneiro AM. Serotonin transporter and integrin beta 3 genes interact to modulate serotonin uptake in mouse brain. Neurochemistry international. 2014;73:122-6.

Epub 2013/10/03.

15. Oved K, Morag A, Pasmanik-Chor M, Oron-Karni V, Shomron N, Rehavi M, et al.

Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics.

2012;13(10):1129-39. Epub 2012/08/23.

Photo by Kfir Ziv 026

miRNA profiling for prediction of antidepressant response

ECNP Daily News Saturday 13

www.ecnp-congress.eu

TRANSLATIONAL RESEARCH

S.07: Translational insights into compulsivity Forum Sunday 09:00–10:40

Getting to the roots of compulsivity

C

ompulsivity forms the focal point of a translational research session taking place tomorrow morning, chaired by Jeffrey Glennon (Radboud University Nijmegen Medical Centre, the Netherlands) and Joseph Zohar (Tel Aviv University, Israel). The session will explore a number of current investigations that are succeeding in tying together compulsivity’s heterogeneous origins, with cross-diagnostic comparisons reinforcing the notion that a dimensional approach to psychiatry lays a fruitful stepping stone towards novel therapeutic targets.

Among the work under discussion is TACTICS (Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes1), an EU FP7 consortium which aims to identify the neural, genetic, and molecular factors involved in the pathogenesis of compulsivity, which Dr Glennon coordinates alongside Jan Buitelaar (Radboud University Nijmegen Medical Centre, the Netherlands). The multidisciplinary venture, which combines 11 partners from seven different countries, combines methods such as structural neuroimaging, neurochemistry, behavioural study, genetics, proteomics and Bayesian machine-learning, in both humans and animals, in order to better understand the underlying mechanisms behind the trait that plays a role in psychiatric disorders such as autism spectrum disorder (ASD) and obsessive-compulsive disorder (OCD), as well as in the drug-seeking behaviours that often emerge in attention deficithyperactivity disorder (ADHD).

Dr Glennon will be presenting recently-uncovered genetic networks underlying compulsivity as part of the TACTICS study. In an interview with ECNP Daily News, he detailed the dynamic nature of the trait that – if properly understood – could be harnessed for a more patient-specific approach to therapy: “We are interested in the switch, in the case of ADHD drug-seeking, from impulsivity to compulsivity – whether it is part of the same trajectory. We are also interested in the common mechanisms across those with different disorder diagnoses that have this compulsive trait. Although there are different kinds of compulsivity, we are interested in whether they have the same pleiotropic mechanisms underlying it.”

TACTICS is now three years into its five-year research cycle. Its overarching proposal, explained Dr Glennon, is that the top-down control of fronto-striatal circuits, underpinned by glutamate-dopamine-serotonin interactions, are altered to give rise to compulsive traits, and that controlling this could be anti-compulsive.

“We have had some interesting results coming out in terms of the genetics and epigenetic mechanisms,” he continued. “In particular, we started to focus on what are named microRNAs – small, non-coding RNA molecules that could basically alter the outcome of whether you see a gene translated into a protein by altering messenger RNA expression.

“We think of these microRNAs as essentially conductors of an orchestra of several genes and that these microRNAs might give us some epigenetic understanding of these compulsive traits. Barbara Franke [Radboud University Nijmegen Medical Centre, the Netherlands], Jan Buitelaar and I started analysing large genome-wide association studies in OCD. From that analysis by Ilse van de Vondervoort and Geert Poelmans, we found that insulin signalling genes played very prominent roles. This association between insulin signalling, their microRNA regulators and compulsivity is confirmed in animal models showing compulsive behaviour.

Conversely, type II diabetes animal models exhibit compulsive behaviour.”

During his talk, Dr Glennon will touch upon the connection between insulin signalling and fronto-striatal networks, linking this together with the epigenetic regulators of insulin genes, where differences have also been found in both humans and animal models of compulsive-like behaviour. Indeed, one of the aims of the TACTICS proposal was to see if elevated glutamate transmission and compulsivity could be substantially linked.

Tied in with this aim is the explicit demonstration of the correlation between overactivity within fronto-striatal circuits and compulsive behaviour. “This is a key goal of our cross-disorder fMRI studies within TACTICS; that we can substantiate that link,” said Dr Glennon. “We had a review paper published in 2015 which showed that glutamate transmission changes in these compulsive disorders across the lifespan.2 So it is really important, then, to understand compulsivity with regards to a particular time point. As a child, an adolescent, or an adult, glutamate tone is very different. Therefore, how you treat that glutamate tone may actually require tailor-made strategies suitable for that age group.

“They should also be suitable in terms of gender effects. We did not know whether these changes in glutamate transmission could hold equally for girls as it does for boys. There was not a lot of literature on this topic when we started the project, so we became particularly interested in exploring this. But particularly with age-

related changes in glutamate transmission, as measured by the Glx signal [the combi- “We are interested in the switch, in the case nation of glutamate and glutamine that is of ADHD drug-seeking, quantified in proton magnetic resonance from impulsivity to spectroscopy (MRS)], you see a very robust compulsivity – whether 2 change across time.” it is part of the same To move beyond this review, which trajectory.” looked at 59 individual studies in order Jeffrey Glennon to reach the hypothesis of age-related changes in fronto-striatal glutamatergic circuits, Dr Glennon and colleagues are now acquiring their own MRS data across different diagnostic categories: ASD, OCD and ADHD. Currently, explained Dr Glennon, they are substantiating the level of interaction that lies between the genetic mechanisms related to glutamatergic genes and fronto-striatal changes. Furthermore, to address novel treatment strategies in juvenile compulsivity, the TACTICS researchers (notably Ralf Dittmann of “It is really important the Central Institute for Mental Health, to understand Mannheim, Germany) are embarking on compulsivity with Phase IIb studies to determine whether the regards to a particular time point. As a child, NMDA receptor antagonist memantine is an adolescent, or an anti-compulsive in clinical cohorts. adult, glutamate tone is “TACTICS is really a story related to very different.” glutamate- and insulin-related signalling,” concluded Dr Glennon. “And that is Jeffrey Glennon something that we are very excited about because this connection between insulin, glucose metabolism and compulsivity is not something that was really very prominent in the literature. We think this is an exciting way to think about compulsivity.”

More details on the TACTICS consortium can be found at tactics-project.eu References 1. TACTICS (Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes. http://tactics-project.eu 2. Naaijen J et al. Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: a review of magnetic resonance spectroscopy studies.

Neurosci Biobehav Rev. 2015 May;52:74-88.

14 ECNP Daily News Saturday

www.ecnp.eu

TRANSLATIONAL RESEARCH

S.07: Translational insights into compulsivity Forum Sunday 09:00–10:40

Neuroimmunological regulators of compulsivity

T

omorrow morning’s of DAT-directed aAbs could in symposium, ‘Transsome way be associated with lational insights into their targeting the brain and compulsivity,’ concludes with thus affecting changes in proGiovanni Laviola (Istituto Sucedural memory, if not even in periore di Sanità, Rome, Italy) the formation and expression discussing his recent work on of behavioural habits, in huidentifying the neuroimmuno- man subjects as well.” logical regulators of compulJust how far these mechasivity. Dr Laviola and colnisms can be ascribed to the leagues have published a series precipitation of analogous beof works over the past decade haviours in human psychiatric exploring the consequences of illness, relative to other factors, immune disruption in animal remains a knotty question; but models, and he related these the field is young, with clues findings to compulsive behavabundant in the literature: iours during an interview with “Some psychiatric conditions ECNP Daily News. linked to some autoimmune Dr Laviola began by forms of encephalitis have describing the emergence of been ascribed to, for example, his present ideas: “Everything NMDA-aAbs and/or AMPAstarted almost 10 years ago, aAbs. But nothing is known yet with the input of a Russian for DAT-aAbs. colleague, Dr Oleg Granstrem “For ADHD-related symp[Pavlov’s State Medical Unitoms, the only study available versity, St. Petersburg, Russia], who was working at Emory University [Atlanta, USA] with “Some psychiatric Professor Svetlana Dambinova. conditions linked to some autoimmune forms of They were interested in the encephalitis have been detection of autoantibodies ascribed to, for example, (aAbs) against various glutaNMDA-aAbs and/or mate receptors as a diagnostic AMPA-aAbs. But nothing tool for ischemic stroke conseis known yet for DATquences and prevention.” aAbs.” While doing so, Dr GranGiovanni Laviola strem also designed small fragments corresponding to the sequence of the dopamine transporter (DAT) protein, so far is our own, in which we based on the most likely extra- investigated affected children cellular location of an epitope with or without methylphenisupposedly bound by aAbs. date administration therapy.

With these DAT-derived It should also be noted that fragments in their hands, Dr we reported the behavioural Laviola (along with colleague landmarks and plasma levels of Walter Adriani of Rome’s DAT-aAbs interacting with the Istituto Superiore di Sanità) presence of polymorphisms conducted a repeated imin the DAT protein (the varimunisation study in mice.1 able number tandem repeat “As expected, the immunised (VNTR) alleles). This means animals were found to actively that autoimmune mechanisms generate DAT-directed aAbs,” in this case are not likely to act recalled Dr Laviola. “Notably, alone – rather, they interact their immune activation was with genetic factors.”2 accompanied by profound The basis of behaviours changes in behaviour – the characteristic of ADHD – flexibility to shift a choice in alongside compulsive behavoperant paradigm settings, as iours in substance abuse, gamwell as slight hyperactivity and bling disorder, hypersexuality, altered dopaminergic paramOCD, Tourette’s syndrome, and eters in the striatum. others – is a leading research “It was then easy to specutheme. Moreover, explained late that the presence in plasma Dr Laviola, the possibility

ly-driven overproduction of DAT. The elevation in DATaAbs may well be considered as an adaptive process aimed to counteract the excessive DAT levels. If this is true, autoimmunity should be regarded not as a pathology, but instead as a ‘normal’ homeostatic process.

The pathology may stem from

“As is the case in multiple sclerosis, wherein a cell clone starts to produce aAbs against myelin, is it not possible that another cell clone could produce aAbs fighting against dopamine terminals in the striatum?”

Giovanni Laviola

that aAbs might tap directly into neural striatal circuits is intriguing.

Drs Laviola and Adriani’s 2012 paper outlines some of the mechanisms by which immune insults on the brain might be mediated1. Considering the notion that the immune system is continuously involved in the formation of autoantibodies, Dr Laviola described how this might in some select circumstances lead to psychopathology: “Normally, the cell clone producing an aAb will be terminated, because the target epitope is recognised as ‘self ’. But – as is the case in multiple sclerosis, wherein a cell clone starts to produce aAbs against myelin – is it not possible that another cell clone could produce aAbs fighting against dopamine terminals in the striatum?

“In the case of the DAT 10/10 polymorphism, it is likely that there is a genetical-

a disruption of this immune control over genetic expression of a protein.”

Dr Laviola believes that aAbs could be harnessed as biomarkers of immune processes regulating neurotransmission proteins such as DAT, and perhaps even dopamine receptors, with non-invasive peripheral measures providing a window on goings on within the brain.

He also noted that brain DAT function is highly relevant with respect to vulnerability to compulsive syndromes, as well as to some addictive behaviours, to ADHD, and to risk-taking and sensation-seeking vulnerabilities.

“We may predict that elevation in DAT-aAbs titres could be useful to screen for people with a given behavioural profile, likely to engage in ‘risky business,’ for instance. Imagine what avenues could be opened if the screening for DAT-aAbs would allow us to distinguish those whose immune issues go on to precipitate psychiatric illness from those who do not!”

References 1. Adriani W et al. Immunization with DAT fragments is associated with long-term striatal impairment, hyperactivity and reduced cognitive flexibility in mice. Behav Brain Funct. 2012;8: 54.

2. Giana G et al. Detection of auto-antibodies to DAT in the serum: interactions with DAT genotype and psycho-stimulant therapy for ADHD. J Neuroimmunol.

2015;278:212-22.

ECNP Daily News Saturday 15

www.ecnp-congress.eu

ECNP

The ECNP Office

Behind the scenes at the ECNP Congress

E

ach year, a wealth of individuals work closely together to ensure that the annual ECNP Congress runs smoothly in its temporary home. Every detail, from venue choice to scientific programme, from budget to room layout, and even what food to serve at the Welcome reception must be worked out in advance, and there are a myriad of links in the chain that need to be in place – often with little time to spare. “We’ve had some tight planning this year, as the congress has been moved earlier, to August,” recalls Godelieve Escartin, Project Manager for Congresses and Meetings at the ECNP Office.

“But our very committed and experienced team at the ECNP Office – and the dedicated individuals at Colloquium Brussels (who handle many aspects such as registration, hotel reservations and onsite management) – have made it possible to arrange everything on time!”

Ms Escartin, alongside another dozen members of the core ECNP Office, collectively oversee all scientific, communicative, educational and operational aspects of the college, its meetings and initiatives. With emphasis on rotational, structured experience, it means each year may see a different person taking the lead on projects such as the ECNP Congress.

And the 28th ECNP Congress in Amsterdam will mark a landmark 10th year for Ms Escartin, giving her a special perspective on how the ECNP Office has developed in the last decade. “During those 10 years I have witnessed many changes and improvements at ECNP,” she said. “Every year new projects and initiatives are born, and it is always a challenging yet rewarding process to be able to realise them in the best possible way.

“I have always worked in the logistics team, and when I started we organised three to four meetings besides the annual congress, with many tasks done by our contracted congress organisers. Now a decade later, we

organise around 15 meetings besides the congress, and almost all of the tasks are handled by the ECNP Office.”

Of course, the ECNP Office also relies on a vast and varied collection of other people to make each meeting – particularly the Congress – a success: “Without all of the volunteers from each of the different committees, we would not be able to organise a congress with such a high level of scientific excellence,” said Ms Escartin.

“The Scientific Programme Committee, and especially its chair Wim van den Brink, are in very close contact with my colleagues at the office to make sure there is a scientific

“Without all of the volunteers from each of the different committees, we would not be able to organise a congress with such a high level of scientific excellence.”

Godelieve Escartin

programme filled with nothing but the best speakers. Thanks to them we have a very well-balanced programme, and a very high level of science at our congress.

“A project manager can not realise a successful project without a good team, and once again my colleagues at the Office, at Colloquium Brussels, and also our main suppliers (which we use every year) make it so much easier to realise such a large and complex project.”

As each year beckons, the organisational team are also tasked with implementing any new initiatives that are introduced at the Congress, and in 2015 there are several new updates: “Every year we try to improve the programme of our congress, and we try to implement new topics, sessions or other ideas,” said Ms Escartin. “This year we introduce the EUFAMI session, held at 14:00 on Saturday, as we also would like to focus on the other side of brain disorders: the role of the family carer.

“Furthermore, we also wanted to give more emphasis to the Career development sessions, thus we moved them to a lunchtime slot, and relocated them to the thriving poster area. In these sessions, advice will be given by senior members on aspects such as how to make a good poster, a stand-out presentation, or how to forge a career outside of research – topics which are especially interesting and useful for junior scientists.

“In addition, every year we try to improve not only the scientific parts of the congress, but also all other parts, like the app. To that end, this year we introduce the ECNP App, which incorporates the congress as always, but also encompasses other meetings, meaning the app can be used all year round. Furthermore, we’ve improved our eposters, making sure all physical posters are also shown in e-poster format, and keeping the award area exclusively as an e-posteronly area.”

ECNP Office Executive Director Alexander Schubert, PhD

Science, Education & Communication

Operations

Project Manager Communication

Manager Operations

Congresses & Meetings

Ligia Bohn

Ellen van den Berg

Project Manager Science, Education & Communication

Administrative Assistant

Petra Hoogendoorn

Laura Lacet

Project Manager Science & Education

Bookkeeper

Corine ten Brink Nathalie Buitenhuis

Margreeth Bos-Oosterbroek

Manager Congresses & Meetings

Iris Allebrandi Project Managers Congresses & Meetings

Godelieve Escartín Melinda Spitzer Jolijn van Middelkoop Eline Dimmendaal Assistant Manager Meetings

Marlies Tissen

Project Manager Strategic Projects Administrator Expert Platform on Mental Health

Annemieke Heuvink

16 ECNP Daily News Saturday

www.ecnp.eu

CLINICAL TREATMENT

S.21: Drug repurposing in CNS: how to maximise the benefits Auditorium Tuesday 09:00–10:40

Drug repurposing: The US experience

D

uring Tuesday’s drug repurposing symposium, co-chaired by Michael Davidson and Jan van Ree, Carla Canuso (Janssen Research & Development, NJ, USA) will be providing an industry perspective on the challenges and successes encountered in drug repurposing initiatives based on experience with the US programme, New Therapeutic Uses, run by the National Center for Advancing Translational Sciences (NCATS).

The New Therapeutic Uses programme1 is a collaborative venture, as Dr Canuso described in conversation with ECNP Daily News: “The programme is designed to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutics development,” she said. “The initiative began with a pilot programme in 2012, as part of the NIH’s newly established NCATS. This programme matches researchers with a selection of pharmaceutical industry assets to test ideas for new therapeutic uses, with the ultimate goal of identifying promising new treatments for patients.”

“[NCATS] matches researchers with a selection of pharmaceutical industry assets to test ideas for new therapeutic uses.”

Carla Canuso

In its pilot programme and a subsequent request for proposals, NCATS posted information on over 75 compounds from eight pharmaceutical companies.2 Academic investigators submitted brief proposals, and the best were selected for review by the pharmaceutical companies. Companies then determined which projects they wished to pursue, and Collaborative Research Agreements were established and full grant proposals were submitted.

Across the pond, the UK’s MRC-Industry Asset-Sharing Initiative3 and ECNP’s Medicines Chest4 follow in a similar vein. And indeed, the willingness of pharmaceutical companies to give investigators access to so-called ‘deprioritised compounds’ has led to

collaborations funded by private foundations as well.

“There are many benefits of this approach for companies, including shorter drug development times and leveraging prior investments to ultimately bring new treatments to patients. There are in fact pharmaceutical companies that focus specifically on drug repositioning by in-licensing assets that are Phase II ready.

“However, larger pharmaceutical companies often must make strategic business decisions around which assets to take forward into full development. Therefore if a compound is not successful in the first indication in which it is tested, it may be ‘deprioritised’ or ‘shelved’. Additionally, while a given company may have expertise in the original indication, it may not possess the same capabilities in another therapeutic area or disease state.”

One key challenge in negotiating with private companies, explained Dr Canuso, is that the enduring value of such compounds must be clearly demonstrated to management and internal partners, in order for them to justifiably renege on previous decisions that led to the discontinued development of these compounds in the first place. “It is important to identify internal allies and champions for each specific proposal,” she added. “These are often individuals who have a history with the compound and are eager to see it tested further.”

Al-

though studies from the New Therapeutic Uses programme are still underway, the programme is already seeing evidence of success, as Dr Canuso: noted “For example, a group of investigators at Yale University School of Medicine demonstrated that a drug originally developed for various cancers can reverse memory deficits and synapse loss found in Alzheimer’s disease mouse models.5 “A subsequent clinical trial of patients with mild-to-moderate Alzheimer’s showed

“It is important to identify internal allies and champions for each specific proposal. These are often individuals who have a history with the compound and are eager to see it tested further.”

Carla Canuso

the compound to be reasonably safe and well tolerated, and able to achieve substantial CNS penetration with oral dosing.6 As a result of this translational line of research, the investigators have recently launched a larger Phase IIa clinical trial of a promising new therapy with a novel mechanism of action.”

This is a welcome tale, and one that sharply contrasts the on-average 14-year slog required from discovery of a therapeutic target to approval of a new drug – a process that is estimated to fail in 95% of cases.

Following its 2012 birthdate, New Therapeutic Uses made its first nine funding agreements in 2013. Encouragingly, five of these pertained to CNS disorders. Another round of funding was released in 2014, and while NCATS funding announcements are currently closed, the high level of investigator response to this grant mechanism will lead to future funding announcements..

Dr Canuso will be presenting ‘The snags and the hitches of starting a trial with a proprietary compound: experience from the NCATS,’ as part of the symposium on CNS drug repurposing taking place on Tuesday morning between 9:00 and 10:40.

References 1. NCATS. https://ncats.nih.gov 2. NCATS 2014 Industry-Provided Assets. http://www.ncats.nih.gov/ntu/assets/current 3. MRC-Industry Asset Sharing Initiative. http://www.mrc. ac.uk/funding/browse/mrc-industry-asset-sharing-initiative/ 4. ECNP Medicines Chest. http://www.ecnp.eu/projectsinitiatives/ECNP-medicines-chest.aspx 5. Kaufman AC et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol. 2015 Jun;77(6):953-71.

6. Nygaard HB et al. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimers Res Ther. 2015 Apr 14;7(1):35.

ECNP Daily News Saturday 17

www.ecnp-congress.eu

THE 28TH ECNP CONGRESS

Rapid-fire posters

Rapid-fire posters offer snapshots of exemplary research

A

fter first being implemented at last year’s ECNP Congress in Berlin, the Rapid-fire (RF) poster sessions will return this year, giving 18 of the highest-scoring poster presenters the chance to exhibit an e-poster of their work in front of an audience.

Each RF poster presenter is selected based on the quality of their abstract, and receives this added exposure in addition to their participation in the usual poster sessions. Held on Sunday, Monday and Tuesday between 12:15–12:45, each RF poster session will feature six speakers, for five minutes each.

ECNP Daily News caught up with one presenter from each of the three sessions to find out more about the kinds of studies these exemplary posters will be showcasing.

Mireia Rabella Figueras

L’Institut de Recerca del Hospital de Sant Pau, Barcelona, Spain In the first Rapid-Fire Poster session, held on Sunday, Ms Rabella Figueras will describe her work centred on the neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder, and its pharmacological reversal.

As she details in her poster abstract, schizotypal personality disorder (SPD) is a schizophrenia-spectrum disorder characterised by odd or bizarre behaviour, strange speech, magical thinking, unusual perceptual experiences, and social anhedonia. Schizophrenia itself has been associated with anomalies in dopaminergic neurotransmission, as well as deficits in neurophysiological markers of executive function, such as error-related negativity (ERN), a component of an event-related potential (ERP).

ERN manifests after performance errors, therefore it is considered a correlate of behavioural monitoring. It relies on adequate fronto-striatal

function, is dopamine sensitive, and thus SPD and schizophrenia have been proposed to share a common neural basis.

With this in mind, Ms Rabella Figueras implemented a study to investigate whether SPD patients show deficits in behavioural monitoring when compared to healthy controls (as measured by ERN). Crucially, risperidone – an antipsychotic – was also employed to see whether this deficit could be reversed.

“The study was carried out according to a double-blind randomised, cross-over, placebo-controlled design,” she told ECNP Daily News. “SPD and controls participated in two different experimental sessions in which they were tested after receiving a placebo (lactose capsule) or an oral dose of 1mg of risperidone.”

She added: “A behavioural task and electroencephalography recording (EEG) were conducted two hours after drug administration, when the peak risperidone plasma levels were expected. A choice reaction time task, the Eriksen flanker task, was then used. Participants were required to respond to the centre letter of a fiveletter array, designated as the ‘target’, with either a left-hand or right-hand response; the goal of this procedure being to aim for a reaction time that would yield approximately 10-15 % of errors. Subjects were encouraged to respond to the stimuli as fast as possible and to correct their errors as fast as possible whenever they detected them.”

As Ms Rabella Figueras described, in the absence of risperidone, the analysis of behaviour from both groups showed that, under placebo, performance was worse in the SPD group, with significantly-slower reaction times, and increased time taken to correct errors.

After risperidone administration, SPD patients showed reduced correction time, but interestingly, correction time

increased in the control group.

“Thus, risperidone normalised patients’ behavioural performance,” she said.

“The same effect was observed in ERN amplitude: While risperidone reduced ERN amplitude in controls, it was increased and restored in patients. As such, deficits on behavioural monitoring in SPD patients, measured with ERN, were reversed with risperidone.”

Describing the clinical implications of the findings, Ms Rabella Figueras stressed that the study gave credence to the use of ERN as a measure of predicting response to risperidone in psychotic spectrum disorders. “This biological marker of predisposition to psychosis should be included as a predicting response variable to the pharmacological treatment with risperidone,” she said, adding: “This would be useful in naïve first-episodes of psychosis, in which adequate pharmacological treatment only could be found through trial and error.

“In this case, risperidone could be an indicate treatment for patients with deficits in ERN. Similarly, It would be useful include ERN measures in Ultra-High-Risk patient follow-ups to control and study further this variable along the illness process.”

“… deficits on behavioural monitoring in schizotypal personality disorder patients, measured with ERN, were reversed with risperidone.”

Mireia Rabella Figueras

Matthias Kirschner

Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zürich, Switzerland On Monday, Dr Kirschner will join his fellow RF poster presenters to discuss his work evaluating self-regulation of the dopaminergic reward system, and its implication for cocaine addiction. “Cocaine addiction is a severe chronic disorder influencing neuroplasticity in the dopaminergic reward circuits1,” began Dr Kirschner. “These maladaptive neuronal changes contribute to compulsive drug

“… if neurofeedback training effectively enhances dopaminergic sensitivity for non-drug related rewards in cocaine users, this could be a novel treatment strategy to reduce drug-using behaviour in cocaine addiction.”

Matthias Kirschner

use and reduced sensitivity to previously rewarding life situations or natural reinforcers.2 In contrast to this, sensitivity to drug cues is enhanced.

However, until now, treatment of cocaine addiction is limited and often ineffective.

“Recent research in the field of real-time fMRI (rtfMRI) revealed a novel method to self-regulate key structures in the dopaminergic reward system, i.e. neural activity in the substantia nigra and ventral tegmental area (SN/ VTA), with positive mental imagery.3 This self-regulation of SN/VTA can be trained and improved via rtfMRI mediated neurofeedback.4 “For the first time, we tested this innovative method in a clinical population of cocaine users (CUs) to evaluate its potential capability as a novel treatment strategy. We tested i) whether CUs are able to self-regulate SN/VTA activity by imagination of non-drugrelated cues, and ii) if CUs can improve this self-regulation ability with rtfMRI neurofeedback training. If feasibility of this approach is demonstrated in CUs, it might have the potential to improve therapeutic options in cocaine addiction, and patients may be able to increase their sensitivity to natural and non-drug related reinforcers in SN/VTA, i.e. in Continued on page 18

18 ECNP Daily News Saturday

www.ecnp.eu

THE 28TH ECNP CONGRESS

Rapid-fire posters

Rapid-fire posters offer snapshots of exemplary research

reduce drug-using behaviour in cocaine addiction.”

In his closing remarks, Dr Kirschner emphasised that future research and clinical studies would be needed to establish the effectiveness of this approach and its potential clinical use. He described some of this potential future work: “We aim to evaluate the association between self-regulation of neural activity within SN/VTA and the sensitivity of this region to drug-related cues as assessed in a drug-cue reactivity task within the same participants.

“Finally, we are aiming to test if neurofeedback-assisted training of self-regulation of the reward system can reduce cocaine use in a future clinical study.”

Continued from page 17

brain regions usually activated by drug cues.”

Using a cross-sectional design comprising CUs, and matched healthy controls, participants were advised to voluntarily upregulate neural activity in the SN/VTA via positive mental imagery.

During an rtfMRI task, visual feedback of neural activity was provided. The main outcome measure from the study was the increase in blood oxygenation-level dependent (BOLD) activity induced by positive mental imagery in the SN/VTA and related regions.

Each participant underwent four functional runs (a baseline run without feedback, two runs with feedback, and a transfer run without feedback), with each run subdivided into nine blocks of alternating ‘Rest’ (20 s) and positive imagery (or “Why is it that some ‘Happy Time’; 20 s), totalling people can use cannabis approximately six minutes. heavily for 20 years and As Dr Kirschner described, still function properly, and others can’t take cannabis so far 12 participants with once without having cocaine use higher than 1g/ paranoid symptoms, or week (for at least 6 months) develop psychosis?” and 14 healthy controls were included in the ongoing study.

Erika van Hell “We successfully implemented the novel rtfMRI method previously developed by Sulzer et al.4 for healthy controls in a clinical population of CUs, and all participants completed the full session and were able to perform the rtfMRI mediated neurofeedback task.”

Briefly touching upon the Ms Rabella Figueras, Dr Kirschmain findings, he continued: ner and Dr van Hell will join a “One, we replicated findings total of 18 speakers in this year’s from Sulzer et al.4, showing that three Rapid-fire poster sessions, healthy participants are readily taking place on Sunday-Tuesday able to self-regulate activity between 12:15 and 12:45 at the within in their brains’ reward Poster Podium. systems. Two, we extended the References 1. Kalivas PW, O’Brien C. Drug work of Sulzer et al. by showing addiction as a pathology of staged for the first time that cocaine us- neuroplasticity. Neuropsychopharmacology. 2008;33:166–80. ers are also able to self-regulate and activate their reward system 2. Volkow ND, Baler RD, Goldstein RZ. Addiction: pulling at the neural by positive imagery of non-drug threads of social behaviors. Neuron.

2011;69:599–602. related cues. This constitutes 3. Sulzer J, et al. Real-time fMRI neuthe first step towards the use of rofeedback: progress and challenges. rtfMRI self-regulation as novel Neuroimage. 2013a;76:386–99.

4. Sulzer J, et al. Neurofeedbacknon-invasive treatment strategy mediated self-regulation of the in cocaine addiction. dopaminergic midbrain. Neuroimage.

2013b.83C, 817–825.

“Three, preliminary results

Erika van Hell

suggest that both groups, healthy controls and cocaine users, are able to improve selfregulation of neural activity in the dopaminergic midbrain based on rtfMRI mediated neurofeedback. So far, we did not observe any group difference between healthy controls and cocaine users in our preliminary analysis including only 12 and 14 participants per group.”

With this in mind, Dr Kirschner went on to comment on the implications for cocaine addiction, first highlighting that dysfunction of the dopaminergic reward system, especially an imbalance between high drug and drug cue sensitivity, and reduced response to non-drug related rewards, have been suggested to be a core deficit in cocaine addiction. “In patients with cocaine addiction this dopaminergic imbalance may contribute to the tendency to favour drug taking behaviour instead of non-drug related life situation (e.g. social activities with family),” he said.

“Therefore, if neurofeedback training effectively enhances dopaminergic sensitivity for non-drug related rewards in CUs, this could be a novel treatment strategy to

Oldebroek, the Netherlands In the final RF poster session, held on Tuesday, Dr van Hell will be presenting work that has been investigating how two important constituents of cannabis, Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD), affect brain activity during rest.

“THC is associated with cognitive deficits particularly in the areas of memory and attention,” she told ECNP Daily News.

“Generally, reaction times increase, more mistakes are made, and complex tasks in terms of dividing attention between several things is more difficult.

“In addition, THC is psychoactive, which means that acutely, perception changes (sounds can change, colours can change, people can hear voices or things that other people can’t hear), or people can become paranoid or anxious. These effects are not associated with the administration of CBD.” Dr van Hell went on to frame the genesis of her study, noting: “CBD has gained interest in recent years as it seems to be counteracting some of the effects that are caused by THC. One interesting finding is that CBD works as an anti-psychotic, and as such, might be a helpful addition to the medication that is currently available for schizophrenia patients.”

The overall aim of the large

study which Dr van Hell has been involved in is the exploration of the link between cannabis and psychosis, and the development of schizophrenia.

“Why is it that some people can use cannabis heavily for 20 years and still function properly, and others can’t take cannabis once without having paranoid symptoms, or develop psychosis?” she said.

“One question we had was how it works with the combination of THC and CBD – we know quite a bit about THC, and there is more and more about CBD, but the actual combination of the two has never really been under systematic investigation … so that’s what we have tried to do.”

She added: “We were interested in the combination, because there are indications that there are less psychotic symptoms, and less anxiety in people who generally use cannabis with higher levels of CBD.” Dr van Hell performed a double-blind, cross-over, placebo-controlled study with 15 frequent cannabis users, 15 infrequent users/nonuser controls, tested with five randomised drug sessions with a one week washout. Subjects received: a) placebo; b) THC alone; c) CBD alone; d) Lowdose THC and CBD in combination; and e) High-dose THC and CBD in combination. EEG was used to measure 32 channels across the scalp during five minutes of rest, before and after drug administration.

Results showed that administration of acute THC, and to a lesser extent CBD, increased resting-state brain activity, but CBD in combination with THC could normalise brain function. There was reduced alpha power in the EEG at rest for the frequent users when compared to infrequent, thus indicating chronic cannabis use is linked to altered brain function, and is also likely to change cannaboid sensitivity.

Dr van Hell noted a takehome message from these data: “As CBD in combination with THC can normalise brain function, this is important to keep in mind when using CBD as medication.”

ECNP Daily News Saturday 19

www.ecnp-congress.eu

ECNP

ECNP

Wordsearch

Issue 2

Filled with highlights, interviews and live coverage of the Congress so far

ECNP DAILY NEWS

Available Sunday morning!

ECNP Daily News Publishing and Production MediFore Limited President Guy Goodwin Editor-in-Chief Peter Stevenson Editors Ryszarda Burmicz Aisling Koning Additional content Becky McCall ECNP Office Petra Hoogendoorn Godelieve Escartin

Wordsearch

Can you identify 10 neurotransmitters in the wordsearch below?

Words could appear horizontally (forwards or backwards), diagonally or vertically.

E

I

N T H

I

L N S U T T O

A S E R O T O N

I

N N X N

U N N D N T O O N X Y I

I

E

E N

L O H C L Y T E C A

E T M N N P N S O N P R X

S S A A O A A C

P Y T M O T

C E P H A N A P

A N Y U T T G L A N

L E R P S R U U E M E X Y

I

E N H E M A B A G

N L

I

I

H T O

I M G Y H T E I

T O M T I

E C

Design Peter Williams Head Office 19 Jasper Road London SE19 1ST, UK Telephone: +44 (0) 208 244 0583 editor@medifore.co.uk www.medifore.co.uk Copyright © 2015: ECNP. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, transmitted in any form or by any other means, electronic, mechanical, photocopying, recording or otherwise without prior permission in writing from ECNP and its organisers. The content of ECNP Daily News does not necessarily reflect the opinion of ECNP 2015 Congress Chairman, ECNP Scientific Advisors or Collaborators.

R T

I

I

I

Y P L O M I

I M E C

S P S O Y O S N

Answers will be revealed in Issue 2 of ECNP Daily News

O H

I

A